Copenhagen, Denmark, 30 November 2020 – FluoGuide A/S (“FluoGuide” or the “Company”) has entered into an agreement with Skandinaviska Enskilda Banken (“SEB”) on commissioned research coverage.
Starting today, SEB will initiate its commissioned research, meaning that SEB will continuously monitor and analyze FluoGuide’s operations, its products, markets, and competitors. The initial research report is available here.
FluoGuide A/S is obliged to publish this information in accordance with the EU Market Abuse Regulation. The information was provided by the contact person set out above for publication on 30 November 2020.
For further information:
Morten Albrechtsen, CEO
M: +45 24 25 62 66
ma@fluoguide.com
About FluoGuide
FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s first product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, these improvements will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company is undertaking a proof-of-concept clinical trial (phase I/II) to demonstrate the effect of FG001 in patients with high grade glioma including glioblastoma.
This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 954904.
